THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 84 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $153,714 | -95.1% | 13,700 | -95.5% | 0.00% | -83.3% |
| Q3 2022 | $3,111,730 | +11.9% | 306,850 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $2,780,031 | -22.0% | 306,850 | -17.7% | 0.01% | 0.0% |
| Q1 2022 | $3,565,940 | +69.2% | 373,000 | +95.5% | 0.01% | 0.0% |
| Q4 2021 | $2,108,000 | +30.2% | 190,800 | -12.8% | 0.01% | 0.0% |
| Q3 2021 | $1,619,000 | +222.5% | 218,800 | +1480.8% | 0.01% | +150.0% |
| Q3 2016 | $502,000 | +1334.3% | 13,841 | +332.5% | 0.00% | – |
| Q3 2015 | $35,000 | -16.7% | 3,200 | 0.0% | 0.00% | – |
| Q2 2015 | $42,000 | – | 3,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |